

ALERE INC.  
Form 8-K  
October 24, 2016

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

---

FORM 8-K

---

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 21, 2016

---

ALERE INC.  
(Exact name of registrant as specified in charter)

---

Delaware (State or Other Jurisdiction of Incorporation)	1-16789 (Commission File Number)	04-3565120 (IRS Employer Identification No.)
---	-------------------------------------	--

51 Sawyer Road, Suite 200, Waltham, Massachusetts 02453  
(Address of Principal Executive Offices) (Zip Code)

(781) 647-3900  
(Registrant's telephone number, including area code)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))



Item 5.07 Submission of Matters to a Vote of Security Holders.

On October 21, 2016, Alere Inc. (the “Company”) held a special meeting of holders of shares of the Company’s common stock (the “Special Meeting”). The Company filed its Definitive Proxy Statement for the proposals voted upon at the Special Meeting with the Securities and Exchange Commission (the “SEC”) on September 26, 2016.

As of the close of business on August 24, 2016, the record date for the Special Meeting, there were approximately 86,740,318 shares of the Company’s common stock issued and outstanding and entitled to vote at the Special Meeting. A quorum of 67,865,910 shares of the Company’s common stock was represented in person or by proxy at the Special Meeting. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, with respect to each proposal is set out below:

1. Proposal to adopt the Agreement and Plan of Merger, dated as of January 30, 2016 (the “Merger Agreement”), by and among Abbott Laboratories, the Company and Angel Sub, Inc., a wholly owned subsidiary of Abbott which became party to the Merger Agreement through execution of a joinder agreement to the Merger Agreement on February 2, 2016.

For	Against	Abstain	Broker Non-Votes
-----	---------	---------	------------------

66,764,692	1,014,027	87,191	0
------------	-----------	--------	---

The proposal to adopt the Merger Agreement was approved, receiving the affirmative vote of approximately 77% of the shares of the Company’s common stock outstanding and entitled to vote at the Special Meeting.

2. Proposal to approve, by non-binding, advisory vote, the compensation that may be paid or may become payable to the Company’s named executive officers in connection with, or following, the merger contemplated by the Merger Agreement.

For	Against	Abstain	Broker Non-Votes
-----	---------	---------	------------------

37,519,440	30,005,770	340,700	0
------------	------------	---------	---

The proposal to approve, by non-binding, advisory vote, the compensation that may become payable to the Company’s named executive officers in connection with the merger contemplated by the Merger Agreement was approved, receiving the affirmative vote of approximately 56% of the shares of the Company’s common stock cast affirmatively or negatively on that proposal.

In connection with the Special Meeting, the Company also solicited proxies with respect to the adjournment of the Special Meeting to a later date or time, if necessary or appropriate, to solicit additional proxies if there were insufficient votes at the time of the Special Meeting or any adjournment or postponement thereof to adopt the Merger Agreement. As there were sufficient votes at the time of the Special Meeting to adopt the Merger Agreement, the adjournment or postponement of the Special Meeting to solicit additional proxies for such purpose was unnecessary and such proposal was not submitted to the holders of shares of the Company’s common stock for approval at the Special Meeting.

Item 5.08 Shareholder Director Nominations.

To the extent applicable, the information in the second and third paragraphs of Item 8.01 of this Form 8-K is incorporated by reference into this Item 5.08.



Item 8.01 Other Events.

On October 21, 2016, the Company issued a press release announcing the results of the stockholder vote at the Special Meeting. A copy of that press release is attached hereto as Exhibit 99.1 and incorporated herein by reference. The merger with Abbott remains subject to regulatory approvals and other customary closing conditions.

Additionally, in accordance with applicable law and the New York Stock Exchange Rules, the Company's Board of Directors has established December 8, 2016 as the date of the Company's 2016 Annual Meeting of Stockholders (the "2016 Annual Meeting"). Because the date of the 2016 Annual Meeting has been changed by more than 30 days from the anniversary of the 2015 Annual Meeting of Stockholders, a different deadline applies for submission of proposals by stockholders intended to be included in the Company's 2016 proxy statement and form of proxy. Stockholders of the Company who wish to have a proposal considered for inclusion in the Company's proxy materials for the 2016 Annual Meeting pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), must ensure that such proposal is received by the Company at 51 Sawyer Road, Suite 200, Waltham, MA 02453, Attn: Secretary, on or before the close of business on November 3, 2016, which the Company has determined to be a reasonable time before it expects to begin to print and send its proxy materials. Any such proposal must also meet the requirements set forth in the rules and regulations of the SEC in order to be eligible for inclusion in the proxy materials for the 2016 Annual Meeting. The November 3, 2016 deadline will also apply in determining whether notice of a stockholder proposal is timely for purposes of exercising discretionary voting authority with respect to proxies under Rule 14a-4(c) of the Exchange Act.

In addition, in accordance with the requirements contained in the Company's Amended and Restated By-Laws, stockholders who wish to bring business before the 2016 Annual Meeting outside of Rule 14a-8 of the Exchange Act or to nominate a person for election as a director must ensure that written notice of such proposal (including all of the information specified in the Company's Amended and Restated By-Laws) is received by the Company's Secretary, at the address specified above no later than the close of business on November 3, 2016. Any such proposal must meet the requirements set forth in the Company's Amended and Restated By-Laws in order to be brought before the 2016 Annual Meeting.

Cautionary Statement Regarding Forward-Looking Statements

This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Readers can identify these statements by forward-looking words such as "may," "could," "should," "would," "intend," "will," "expect," "anticipate," "believe," "estimate," "continue" or similar words. A number of important factors could cause actual results of Alere and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, (i) the risk that the proposed merger with Abbott may not be completed in a timely manner or at all; (ii) the possibility that any or all of the various conditions to the consummation of the merger may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the Merger Agreement, including in circumstances which would require Alere to pay a termination fee or other expenses; (iv) the effect of the announcement or pendency of the transactions contemplated by the Merger Agreement on Alere's ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally; (v) risks related to diverting management's attention from Alere's ongoing business operations; (vi) the risk that stockholder litigation in connection with the transactions contemplated by the Merger Agreement may result in significant costs of defense, indemnification and liability and (vii) the risk factors detailed in Part I, Item 1A, "Risk Factors," of our Annual Report on Form 10-K, for the fiscal year ended December 31, 2015 (as filed with the

Securities and Exchange Commission on August 8, 2016) and other risk factors identified herein or from time to time in our periodic filings with the Securities and Exchange Commission. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. We undertake no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

---

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.	Description of Exhibit
99.1	Press Release, dated October 21, 2016

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ALERE INC.**

Date: October 24, 2016 By: /s/ Douglas Barry  
Name: Douglas Barry  
Title: Associate General Counsel

---



EXHIBIT INDEX

Exhibit No.	Description of Exhibit
99.1	Press Release, dated October 21, 2016